2003, Number 4
Next >>
Gac Med Mex 2003; 139 (4)
Hyperhomocysteinemia in Acute Cerebral Infarct.
Millán-Guerrero RO, Vázquez C, Isais-Aguilar L, Trujillo-Hernández B
Language: Spanish
References: 30
Page: 307-310
PDF size: 53.71 Kb.
ABSTRACT
Antecedents: Hyperhomocysteinemia has recently been recognized as contributing
directly or associatively to the arteriosclerotic process in cerebral infarction.
Objective: To determine plasmatic homocysteine levels in with patients with
acute cerebral infarction and to seek an association between clinical sub-types
of cerebral lesion and homocysteine levels and risk factors present.
Material and Methods: A descriptive study was carried out on patients diagnosed
with acute cerebral infarction. The study included 22 patients of both sexes
between the ages of 40 and 85 years. Samples were collected on the second day
of hospitalization after 12 h of fasting.
Results: In 13 of 22 patients, elevated levels of serum homocysteine were found.
The homocysteine average was 20-68
mmol/ L ±
9.6 SD. No association between degree of cerebral lesion and risk factors was
found (p > 0.05).
Conclusion: An increase in homocysteine was found in 59% of cerebral infarction
patients. No correlation between hyperhomocysteinemia and known risk factors
such as smoking, alcoholism, high blood pressure, and diabetes was found. It
is necessary to continue this line of investigation to identify conditioning
factors that elevate homocysteine and to implement measures to lower levels
of hyperhomocysteinemia, thus helping reduce the incidence of cerebrovascular
disease.
REFERENCES
WHO MONICA Project, Principal investigators. The Worid Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. J Clin Epidemiol 1988;41:105-114.
2. Lacy CR, Suh DC, Bueno M, Kostis JB. For the STROKE Collaborative Study Group. Delay in presentation and evaluation for acute stroke: stroke time registry for outcomes knowledge and epidemiology. Stroke 2001;32:63-69.
3. Navarro R. Problemática de la ateroesclerosis en México.Rev Mex Cardiol 1999;10(2):59-63.
4. SIMO. Sistema de Información Médica Operativa. IMSS HGZ Y UMF l; 2001.
5. Bamdford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991;337:1521-1526.
6. Bonita R. Epidemiology of stroke. Lancet 1992;339:342-344
7. Marmot MG, Pulter NR. Primary prevention of stroke. Lancet 1992;339:344-347.
8. Hankey GJ, Eikeiboom JW. Homocysteine and vascular disease. Lancet 1999;354:407-413.
9. Zacarías-Castillo R, Hernández-Rebollar AE, Zajarías-Rabchinskey, González-Bárcena D. Hiperhomocisteinemia, Un nuevo factor de riesgo coronario. Gac Med Mex 2001; 137:335-345.
Lentz SR. Does homocysteine promote atheroesclerosis? Arterioscler Thromb Vasc Biol 2001;21:1385-1386.
Bouhey CJ, Beresford SAA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-1057.
Wilken DEL, Wiiken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest 1976;57:1079-1082.
Brattstróm LE, Hardebo JE, Hulteberg BL. Moderate homocysteinemia-a possible risk factor for arteriosclerotic cerebrovascular disease. Stroke. 1984;15:1012-1016.
Boers GHJ, Smals AGH, Trijbeis FJM, et al. Heterozygosity for homocysteinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985; 313:109-115.
Araki A. Sako, Fukushima Y, et al. Plasma sulfhydryl-containing amino acids in patients with cerebral infarction and in hypertensive subjects. Atherosclerosis 1989;79:139-146.
Malinow MR, Kang SS, Taylor LM, et al. Prevalence of hyperhomocysteinemia in patients with peripheral arterial occlusive disease. Circ Res 1989;79:1180-1188.
Brattstróm L, lsraeisson B, Norving B, et al. Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease- effects of pyridoxine and folic acid treatment. Atherosclerosis 1990;81:51-60.
Brattstróm L, Tengborn L, Israeisson B, et al. Plasma homocysteine in venous thromboembolism. Haemostasis 1991;21:51-57.
Refsum H, Nygard O. Homocysteine and cardiovascular disease mortality. Ann Rev Med 1998;49:31-62.
Wounter MG, Mourrees MT, van der Mooren, et al. Plasma homocysteine and menopausal status. Eur J Clin Invest. 1995;25:801-805.
Subar AF, Harlan LC, Mattson ME. Food and nutrient intake differences between smokers and non-smokers in the United States. Am J Public Health 1990;80:1323-1329.
Weich NG, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042-1050.
Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA 1997;277:1775-1781.
Ueland P, Refsum H, Stabier, et al. Total homocysteine in plasma or serum. Methods and clinical applications. Clin Chem 1993;39:1764:1779.
Howard VJ, Sides EG, Newman GC, Cohen SN, Howard G, Malinow MR, Toole JF. For the stability of plasma homocyst(e)ine in acute stroke patients investigators study changes in plasma homocyst(e)ine in the acute phase after stroke. Stroke 2002;33:473-478.
Hankey GJ, Eikeiboom JW. Homocysteine levels in patients with stroke: clinical relevance and therapeutic implications. CNS Drugs 2001;15:437-443.
Lindgren A, Brattstrom L, Norrrving B, Huitberg B, Andersson A, Johansson BB. Plasma homocysteine in the acute and convalescent phases after stroke. Stroke 1995; 26:795-800.
Kittner SJ, Giles WH, Macko RF, Hebel RJ, Wozniak MA, Wityk RJ, Stolley PD, Stern BJ, Sioan MA, Sherwin R, et al. Homocysteine and risk of cerebral infarction in a biracial population. The Stroke Prevention in Young Women Study. Stroke 1999;30:1554-1560.
Jun-Hyun Y, Chin-Sang CH, Soo-Sang K. Relation of plasma homocyst(e)ine to cerebral infarction and cerebral atherosclerosis. Stroke 1998;29:2478-2483.
Rudd AG, Wade D, Irwin P. The National Clinical Guidelines for Stroke. Stroke 2000;34:131-133.
Full text